BioPorto Diagnostics AS (BioPorto Diagnostics), a subsidiary of BioPorto AS, is an in-vitro diagnostics company that manufactures and markets antibody based products. It's products include matched reagent set, immunoassays, antigens, antibodies and matched antibody pairs, among others. The company offers biology products, NGAL rapid ELISA Kit and Gc-globulin action free ELISA Kit, among others. It also deals with various antibodies with specificity within medical specialties such as obesity, diabetes and primary immune deficiency. The company provides NGAL Test a diagnostic acute kidney injury biomarker which is measured in both human urine and plasma. It markets its products through sales channels and partners. BioPorto Diagnostics is headquartered in Copenhagen, Denmark.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company BioPorto Diagnostics AS
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- BioPorto Diagnostics AS Company Overview
- BioPorto Diagnostics AS Company Snapshot
- BioPorto Diagnostics AS Pipeline Products and Ongoing Clinical Trials Overview
- BioPorto Diagnostics AS - Pipeline Analysis Overview
- BioPorto Diagnostics AS - Key Facts
- BioPorto Diagnostics AS - Major Products and Services
- BioPorto Diagnostics AS Pipeline Products by Development Stage
- BioPorto Diagnostics AS Pipeline Products Overview
- gRAD Test - COVID-19 IgG/IgM
- gRAD Test - COVID-19 IgG/IgM Product Overview
- gRAD Test - Sepsis
- gRAD Test - Sepsis Product Overview
- NGAL (Neutrophil Gelatinase-Associated Lipocalin) Test - Kidney Injury
- NGAL (Neutrophil Gelatinase-Associated Lipocalin) Test - Kidney Injury Product Overview
- Point of Care Test - SARS-CoV-2
- Point of Care Test - SARS-CoV-2 Product Overview
- The NGAL Test - Adults
- The NGAL Test - Adults Product Overview
- BioPorto Diagnostics AS - Key Competitors
- BioPorto Diagnostics AS - Key Employees
- BioPorto Diagnostics AS - Locations And Subsidiaries
- Head Office
- Recent Developments
- BioPorto Diagnostics AS, Recent Developments
- Jul 01, 2024: BioPorto Confirms Market Acceptance of NGAL Products with US Standing Order
- May 14, 2024: First Quarter 2024: Strong growth in US sales of The NGAL Test
- Apr 02, 2024: BioPorto Appoints Peter Morch Eriksen as Permanent Group Chief Executive Officer
- Dec 07, 2023: BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years
- Nov 01, 2023: BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference
- Sep 11, 2023: BioPorto Provides Update on NGAL Test Regulatory Pathway
- Jun 29, 2023: Bioporto Announces Submission of Response to FDA Additional Information Letter
- Nov 11, 2022: BioPorto submits De Novo application to FDA for NGAL test
- Oct 27, 2022: BioPorto exhibiting NGAL biomarker at ASN kidney week - antibodies, ELISA kits, and clinical chemistry assays for early drug development and clinical research
- Jun 28, 2022: BioPorto achieves targeted enrollment in clinical study supporting FDA De Novo Submission for The NGAL Test in the U.S.
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- BioPorto Diagnostics AS Pipeline Products and Ongoing Clinical Trials Overview
- BioPorto Diagnostics AS Pipeline Products by Equipment Type
- BioPorto Diagnostics AS Pipeline Products by Indication
- BioPorto Diagnostics AS, Key Facts
- BioPorto Diagnostics AS, Major Products and Services
- BioPorto Diagnostics AS Number of Pipeline Products by Development Stage
- BioPorto Diagnostics AS Pipeline Products Summary by Development Stage
- gRAD Test - COVID-19 IgG/IgM - Product Status
- gRAD Test - COVID-19 IgG/IgM - Product Description
- gRAD Test - Sepsis - Product Status
- gRAD Test - Sepsis - Product Description
- NGAL (Neutrophil Gelatinase-Associated Lipocalin) Test - Kidney Injury - Product Status
- NGAL (Neutrophil Gelatinase-Associated Lipocalin) Test - Kidney Injury - Product Description
- Point of Care Test - SARS-CoV-2 - Product Status
- Point of Care Test - SARS-CoV-2 - Product Description
- The NGAL Test - Adults - Product Status
- The NGAL Test - Adults - Product Description
- BioPorto Diagnostics AS, Key Employees
- Glossary
- BioPorto Diagnostics AS Pipeline Products by Equipment Type
- BioPorto Diagnostics AS Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Radiometer Medical ApS
- PBN Medicals Denmark A/S
- NSK Denmark ApS
